Latest Us Healthcare Market News

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.

Enlitic has landed a US$1.2 million contract to migrate and standardise millions of medical imaging records for Parkland Health, marking its third major US healthcare win this month.

4DMedical’s advanced lung imaging technology CT:VQ™ has been deployed at the Mayo Clinic, marking the sixth top US academic medical centre to adopt the system within seven months of FDA clearance.

Cyclopharm has secured a multi-site agreement with Northwestern Medicine, marking a major expansion into Chicago’s healthcare market and reinforcing its US growth strategy.

Enlitic has secured a $1.5 million contract to migrate over 71 million clinical files for Penn Medicine Doylestown Health, reinforcing its foothold in the US healthcare IT sector.

Pro Medicus Limited’s U.S. subsidiary has locked in two significant 5-year contract renewals worth a combined minimum of A$40 million, reinforcing its position in the competitive medical imaging market.

Pro Medicus Limited has reported a stellar half-year performance with revenue up 28.4% and a surge in net profit, driven by major US contract wins and strategic investments.

Imricor Medical Systems has taken a significant step toward US market entry by submitting its Advantage-MR EP Recorder/Stimulator system for FDA 510(k) clearance, aiming to enhance MRI-guided cardiac procedures.

Orthocell Ltd reports steady progress in commercialising its nerve repair product Remplir in the US, with sales growth, expanded distributor networks, and manufacturing upgrades underpinning its path to profitability.

Adherium Limited has exceeded its 2025 shipment goals for its Hailie Smartinhaler devices, driven by rapid growth in remote patient monitoring activations and improved US Medicare reimbursement policies.

ReNerve Limited reported a robust 80% increase in quarterly sales driven by strong US market adoption and expanded hospital approvals. The company advances its nerve repair product pipeline with key regulatory milestones and a refreshed board.

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.